👥 HR & Workplace🇮🇳 India
Dr. Reddy's Semaglutide Setback: Weight-Loss Drug Supplies Delayed Until November
Mint·Friday, 10 July 2026
Dr. Reddy's Laboratories has delayed semaglutide supplies due to an active pharmaceutical ingredient (API) issue and has halved its FY27 supply estimate. The company expects shipments to resume by November. It says patient safety and regulatory filings remain unaffected.
Why It Matters
Semaglutide is the active ingredient in blockbuster weight-loss and diabetes drugs. Dr. Reddy's delay is a setback for affordable access to these treatments in India and for the company's revenue targets.
🔒 Potential Impact + source link
Subscribe to unlock the impact analysis and original source for every story.
More from HR & Workplace
- TCS Q1 Results: Flat Growth and Cautious Clients Signal a Tough Year Ahead for Indian IT
- Air India's CEO Is Gone — Tata's Chandrasekaran Steps In With an Interim Team
- Nandan Nilekani Makes His Biggest VC Bet Yet With Fundamentum's Fund III
- 70% of Workers Haven't Seen a Raise in Six Months — and Most Don't Know Why